AU2022275832A1 - Agents for directed conjugation techniques and conjugated products - Google Patents

Agents for directed conjugation techniques and conjugated products Download PDF

Info

Publication number
AU2022275832A1
AU2022275832A1 AU2022275832A AU2022275832A AU2022275832A1 AU 2022275832 A1 AU2022275832 A1 AU 2022275832A1 AU 2022275832 A AU2022275832 A AU 2022275832A AU 2022275832 A AU2022275832 A AU 2022275832A AU 2022275832 A1 AU2022275832 A1 AU 2022275832A1
Authority
AU
Australia
Prior art keywords
moiety
independently
compound
agent
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022275832A
Other languages
English (en)
Inventor
Reese M. CALDWELL
Gene M. Dubowchik
Wieslaw Kazmierski
David Adam SPIEGEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Therapeutics Ltd
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of AU2022275832A1 publication Critical patent/AU2022275832A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022275832A 2021-05-17 2022-05-17 Agents for directed conjugation techniques and conjugated products Pending AU2022275832A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163189522P 2021-05-17 2021-05-17
US63/189,522 2021-05-17
PCT/US2022/029535 WO2022245759A2 (en) 2021-05-17 2022-05-17 Agents for directed conjugation techniques and conjugated products

Publications (1)

Publication Number Publication Date
AU2022275832A1 true AU2022275832A1 (en) 2023-12-14

Family

ID=84140970

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022275832A Pending AU2022275832A1 (en) 2021-05-17 2022-05-17 Agents for directed conjugation techniques and conjugated products

Country Status (11)

Country Link
US (1) US20240252674A1 (https=)
EP (1) EP4340891A4 (https=)
JP (1) JP2024519814A (https=)
KR (1) KR20240012380A (https=)
CN (1) CN117750979A (https=)
AU (1) AU2022275832A1 (https=)
CA (1) CA3219517A1 (https=)
IL (1) IL307799A (https=)
MX (1) MX2023013272A (https=)
PH (1) PH12023553154A1 (https=)
WO (1) WO2022245759A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3219475A1 (en) * 2021-05-17 2022-11-24 Wieslaw Kazmierski Compositions including conjugated therapy enhancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
PL3086814T3 (pl) * 2013-12-23 2020-12-28 Bayer Pharma Aktiengesellschaft Koniugaty środka wiążącego (ADC) z inhibitorami KSP
WO2017042944A1 (ja) * 2015-09-10 2017-03-16 国立大学法人山梨大学 フィラデルフィア染色体陽性（Ｐｈ＋）急性リンパ性白血病（ＡＬＬ）の治療薬又は治療方法
EP3617235B1 (en) * 2017-04-28 2026-02-18 Ajinomoto Co., Inc. Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
MX421628B (es) * 2017-07-26 2025-03-14 Kleo Pharmaceuticals Inc Compuestos abt universales y usos de los mismos
JP7404230B2 (ja) * 2017-09-18 2023-12-25 トラスティーズ オブ ボストン ユニバーシティ ネトーシスおよび好中球活性化を処置するための方法
WO2019241609A1 (en) * 2018-06-15 2019-12-19 Trustees Of Boston University Polypeptide compositions and methods for site-specific targeting of therapeutic agents
AU2020299157A1 (en) * 2019-07-03 2022-01-20 Kleo Pharmaceuticals, Inc. CD38-binding agents and uses thereof

Also Published As

Publication number Publication date
WO2022245759A3 (en) 2023-02-02
MX2023013272A (es) 2023-11-30
KR20240012380A (ko) 2024-01-29
US20240252674A1 (en) 2024-08-01
CN117750979A (zh) 2024-03-22
WO2022245759A2 (en) 2022-11-24
CA3219517A1 (en) 2022-11-24
IL307799A (en) 2023-12-01
PH12023553154A1 (en) 2024-03-11
JP2024519814A (ja) 2024-05-21
EP4340891A4 (en) 2025-07-02
EP4340891A2 (en) 2024-03-27

Similar Documents

Publication Publication Date Title
US20100189727A1 (en) Masking Ligands For Reversible Inhibition Of Multivalent Compounds
JP2020523413A (ja) 操作された抗体化合物およびこれらの抱合体
JP2012514982A (ja) 改変した抗体組成物、それを作製および使用する方法
US8008316B2 (en) Azonafide derived tumor and cancer targeting compounds
EP3668545A2 (en) Prodruggable antibodies, prodrugs thereof, and methods of use and making
US11998612B2 (en) Method for conjugating antibody and physiologically active substance
WO2019127346A1 (zh) 募集抗体并靶向肿瘤细胞的双功能分子
EP4340891A2 (en) Agents for directed conjugation techniques and conjugated products
AU2007278407A1 (en) Protein-binding methotrexate derivatives, and medicaments containing the same
JP6583411B2 (ja) 薬物複合体
Inman et al. Synthesis of N. alpha.-(tert-butoxycarbonyl)-N. epsilon.-[N-(bromoacetyl)-. beta.-alanyl]-L-lysine: Its use in peptide synthesis for placing a bromoacetyl cross-linking function at any desired sequence position
Sheridan et al. Solid‐phase synthesis and cyclization of a large branched peptide from IgG Fc with affinity for FcγRI
US20240238436A1 (en) Compositions including conjugated therapy enhancers
JP4568842B2 (ja) 熱帯熱マラリア原虫のエノラーゼ蛋白質の部分ペプチドの製造方法
US20240156974A1 (en) Compositions and methods for modulation of antibody activity
EP4624487A1 (en) Production of antibodies against protein
Plumpton et al. Site‐directed monoclonal antibodies against the amino terminus of 124‐kDa phytochrome from Avena sativa L.
CN118255900A (zh) 具有抗体募集功能的fgfr1拮抗肽衍生物及其合成和抗肿瘤应用
JP2025528776A (ja) 血液脳関門を通過するための抗体ベースの構造体のｂｂｂシャトルによる部位特異的修飾
EP4662235A1 (en) Method of chemical synthesis of single-chain antibody fragments and products thereby obtained
CA3230220A1 (en) Gip receptor agonist and use thereof
JPH02229200A (ja) 抗アレルギー作用を有するペプチド
JP2007063179A (ja) ニトロベンゼンスルフェニル基含有トリプトファンに対するモノクローナル抗体及びそれを用いた抗体カラム
JPH03133997A (ja) 合成ペプチドおよびその用途